BIOMAT Database Logo BIOMAT Database Logo

Cytogenetic response to alpha-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location. 1995

S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
Department of Haematology, Mater Misericordiae Hospital, Brisbane, Australia.

Alpha-interferon (alpha-IFN) therapy is an effective agent in early chronic phase (ECP) chronic myeloid leukemia (CML), achieving hematologic control in the majority and major cytogenetic response (MCR) (reduction in Ph' +ve metaphases to < 35%) in a substantial minority. Currently no pretreatment markers exist to ascertain likelihood of meaningful response. The site of breakpoint in M-bcr and relationship to prognosis is controversial. Studies have been hampered by variation in definition of breakpoint and difference in treatment protocols. In this study of ECP CML patients, Southern analysis and reverse transcription polymerase chain reaction (RT-PCR) were used to determine breakpoint location. Patients received alpha-IFN (9 x 10(6) units/day) and dose-adjusted hydroxyurea (HU) to maintain granulocyte count between 1.0-2.0 x 10(9)/l for 6 months or more. Twelve of 31 patients entered on the study achieved a MCR. The Sokal index did not predict for cytogenetic response to alpha-IFN. Eight of 11 patients with 5' breakpoint achieved MCR compared to only four of 20 patients with 3' breakpoint (P = 0.007). These results suggest site of M-bcr rearrangement may be predictive of response to alpha-IFN therapy. If verified by further study, this may allow more appropriate use of alpha-IFN with respect to other modalities such as allogeneic transplant.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009857 Oncogenes Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene. Transforming Genes,Oncogene,Transforming Gene,Gene, Transforming,Genes, Transforming
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002874 Chromosome Mapping Any method used for determining the location of and relative distances between genes on a chromosome. Gene Mapping,Linkage Mapping,Genome Mapping,Chromosome Mappings,Gene Mappings,Genome Mappings,Linkage Mappings,Mapping, Chromosome,Mapping, Gene,Mapping, Genome,Mapping, Linkage,Mappings, Chromosome,Mappings, Gene,Mappings, Genome,Mappings, Linkage
D002892 Chromosomes, Human, Pair 22 A specific pair of GROUP G CHROMOSOMES of the human chromosome classification. Chromosome 22
D003582 Cytogenetics A subdiscipline of genetics which deals with the cytological and molecular analysis of the CHROMOSOMES, and location of the GENES on chromosomes, and the movements of chromosomes during the CELL CYCLE. Cytogenetic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
M-BCR breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia.
January 1992, Haematologica,
S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
bcr breakpoint and prognosis of chronic phase chronic myeloid leukemia.
December 1990, Blood,
S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
The bcr breakpoint and chronic phase duration in chronic myeloid leukemia.
January 1992, Acta haematologica,
S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.
March 2013, Medical oncology (Northwood, London, England),
S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia.
August 1993, Leukemia,
S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
Relationship between M-BCR breakpoint position in blast crisis and length of chronic phase in chronic myeloid leukemia.
June 1992, Blood,
S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia.
March 2003, Haematologica,
S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
Prognostic significance of BCR breakpoint location in M-bcr.
August 1991, Leukemia,
S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
BCR-ABL breakpoint and prognosis in chronic myeloid leukemia.
May 1992, Blood,
S L Elliott, and K M Taylor, and D L Taylor, and R L Rodwell, and B F Williams, and M M Shuttlewood, and S J Wright, and P E Eliadis, and I H Bunce, and T J Frost
Chronic myeloid leukemia, BCR/ABL transcript, response to alpha-interferon and survival. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.
October 1995, Leukemia,
Copied contents to your clipboard!